Irreversible non-selective MAO inhibitor (amphetamine-related)

Plain-language summaryIntrigue 65 / 100

Tranylcypromine (Parnate) is a first-generation MAOI from 1961 with a chemical backbone closely related to amphetamine. That structural quirk gives it a small but real direct stimulant component on top of the MAO inhibition, producing faster onset (1 to 2 weeks rather than the 4 to 6 weeks typical of MAOIs) and a more activating subjective profile than phenelzine. It carries the same dietary tyramine restrictions and drug interaction risks as the rest of its class. Like phenelzine it earns its place in the modern psychiatric armamentarium specifically for treatment-resistant depression cases where everything else has failed. The recent Tranylcypromine in Treatment-Resistant Depression literature has revived interest in disciplined modern use of these older drugs. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

41/100

Decades-old irreversible MAOI with real clinical history but negligible frontier research appeal

Look, tranylcypromine is a compound researchers already know. FDA-approved in 1961 under Parnate, it was the first non-hydrazine MAOI and carries a structurally unusual cyclopropylamine scaffold that bears a family resemblance to amphetamine. That amphetamine relationship is actually what makes it marginally more interesting than phenelzine on paper: in addition to irreversible MAO-A and MAO-B inhibition, it produces weak monoamine release, which probably explains the faster clinical onset (1 to 2 weeks versus 3 to 6 for phenelzine) and the mildly activating subjective profile investigators and clinicians have described for decades.

The mechanism, though, isnt novel. Irreversible non-selective MAO inhibition is 60-year-old pharmacology. The tyramine cheese effect is a textbook drug interaction. Plasma half-life is short (1.5 to 3.2 hours) but enzyme recovery is slow (5 to 10 days), which creates the dietary and drug-interaction burden that has made this class clinically awkward and commercially marginal since SSRIs came along. For a bench scientist, that interaction profile isnt interesting, its inconvenient background noise.

Where it retains real, if modest, value is as a reference compound. If your program is probing MAO biology, monoamine release, or you need a positive control in a dopaminergic assay, tranylcypromine is a well-characterized tool with known selectivity and a deep pharmacokinetic record. The (-)-trans isomer is the pharmacologically dominant form; the clinical preparation is racemic, which opens a stereochemistry question that’s occasionally been worth pursuing. And the cyclopropylamine scaffold itself has inspired structural analogs in newer programs, so investigators doing scaffold-level work sometimes keep it on the bench as a structural reference.

We dont think it belongs at the center of a serious research program right now. Treatment-resistant depression is genuinely interesting territory, and MAOIs are experiencing mild clinical rehabilitation in TRD discussions, but that reappraisal largely benefits phenelzine data and the class generally rather than generating new mechanistic questions specific to tranylcypromine. The frontier in TRD has moved toward ketamine, psychoplastogens, and the early GLP-1/neuroinflammation angle. If youre studying MAO biology specifically, selegiline gives you selective MAO-B inhibition for a cleaner dissection. If youre studying irreversible MAO-A, phenelzine has deeper clinical literature.

Tranylcypromine is a mature, approved drug with decades of human data. That means the evidence quality is better than most compounds in this library, and the translational signal is real. But research-merit scoring isnt about knowing a compound works. It’s about whether theres something left to discover. Here, the well is mostly dry.

Novelty: 18
Mechanism promise: 32
In-category differentiation: 38
Evidence quality: 60
Translational signal: 58
Research bench value: 55

Rationale Tranylcypromine scores low on novelty and mechanism because non-selective irreversible MAO inhibition is thoroughly mapped 1960s pharmacology, and the amphetamine-like dual mechanism is a curiosity rather than a research catalyst. Its bench value as a non-hydrazine MAOI reference compound and positive control in monoamine release assays keeps the overall from falling below the low forties, but theres no active frontier here.

Irreversible non-selective MAO inhibitor (amphetamine-related)

A non-hydrazine cyclopropylamine MAOI structurally related to amphetamine; rapid-onset compared to phenelzine.

Abstract

Tranylcypromine ((1S,2R)-2-phenylcyclopropan-1-amine; CAS 155-09-9; molecular formula C9H11N; molecular weight 133.19) is a non-hydrazine cyclopropylamine MAOI approved by the FDA in 1961 under the trade name Parnate. The cyclopropylamine scaffold is structurally related to amphetamine, producing weak monoamine release in addition to MAO inhibition; the result is faster antidepressant onset (1 to 2 weeks) than phenelzine (3 to 6 weeks) and a mildly activating subjective profile. Inhibition of both MAO-A and MAO-B is irreversible, with similar tyramine cheese-effect risk. Plasma half-life is 1.5 to 3.2 hours, but enzyme inhibition persists for 5 to 10 days. The (-)-trans isomer is the predominant active form; clinical preparations are racemic. Hepatic metabolism is minor; the compound is largely excreted unchanged. Approved for major depressive disorder; used in atypical and treatment-resistant depression. Used as a non-hydrazine MAOI reference compound and as a positive control in dopaminergic and norepinephrine release studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-227Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Irreversible non-selective MAO inhibitor (amphetamine-related)

Tranylcypromine

Abstract

Read the full monograph